RV 521

Drug Profile

RV 521

Alternative Names: RV-521

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReViral
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 18 May 2018 Updated efficacy data from a phase IIa trial in Respiratory syncytial virus infection presented at the 114th International Conference of the American Thoracic Society(ATS-2018)
  • 05 Feb 2018 Positive efficacy and adverse events data from a phase IIa trial in Respiratory syncytial virus infections released by ReViral
  • 31 Oct 2017 ReViral completes a phase II trial in Respiratory syncytial virus infections (In volunteers) in United Kingdom (PO) (NCT03258502)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top